Trontinemab is a very exciting experimental drug, showing great promise in rapidly clearing Alzheimer’s amyloid plaques from the brains of affected individuals, with remarkably little side effects.
See why Cognito’s headset received FDA Breakthrough Device Designation for addressing cognitive and functional symptoms associated with Alzheimer’s.
Walk through the various steps that occur as a person participates in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project.
“It is exciting to see efficacy of potential new drugs for Dementia with Lewy Bodies, the most common dementia after Alzheimer’s. It is a huge area of unmet need,” said Dr. Marwan Sabbagh.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
Doctors routinely diagnose and track dementia. “Neuropsychological tests” are non-invasive, using interviews or paper/pen tests. More invasive diagnostics include powerful MRI and PET scans.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
CLINICAL TRIALS VIDEO: Thin electrical wires were surgically implanted in the brain of Alzheimer’s patients. Called “Deep Brain Stimulation”, see how this brain “pacemaker” improves
VIDEO + ARTICLE: An award-winning director joins the nation’s largest independent registered investment advisory firm to film a documentary on clinical trials by diet guru
Anticholinergic drugs have been consistently linked to cognitive impairment. Scientists seek de-prescribing trials to test anticholinergic drugs as reversible risk factors for dementia. Can de-prescribing
A powerful song about an 80-year-old professor losing memory due to Alzheimer’s. A tribute and a call for understanding, love, and support.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
MEMORY PROBLEMS, an early sign of Alzheimer’s, are linked to glucose sugar deprivation in brain cells. So is diabetes, a well-known Alzheimer’s risk factor. How strongly connected is the Alzheimer’s-Sugar-Diabetes triangle?
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor